Core Viewpoint - The company reported a decline in both revenue and net profit for the first half of 2025, attributed to capacity expansion efforts that temporarily reduced product supply [1] Financial Performance - The company achieved operating revenue of 986 million yuan, a year-on-year decrease of 13.18% [1] - The net profit attributable to shareholders was 236 million yuan, down 27.89% year-on-year [1] Capacity Expansion - The company has been experiencing rapid growth in plasma collection, leading to insufficient production capacity to meet operational needs [1] - Two wholly-owned subsidiaries, Guangdong Shuanglin and Paisfiko, are both advancing their phase II capacity expansions [1] - Paisfiko completed its phase II capacity expansion and acceptance testing before the 2025 Spring Festival, successfully commencing production in early March [1] - Guangdong Shuanglin also completed its phase II capacity expansion and acceptance testing, with successful production starting in June [1] - The total annual production capacity of the company has increased to over 3,000 tons [1]